Advertisement

Stevens Johnson Syndrome – “Steven Who? And Why I Should Care About His Johnson?”

  • Zachary E. Cardon
  • Colin G. Kaide
  • Jason J. BischofEmail author
Chapter

Abstract

Diagnosing rashes in the emergency department can be challenging. If the rash is extensive and targetoid, include Stevens-Johnson Syndrome (SJS) on your differential and be sure to obtain a thorough history to identify possible offending agents. Additionally, prioritize supportive care and obtaining a dermatology/burn consult to coordinate appropriate care.

Keywords

Rash Steven-Johnson Syndrome Toxic Epidermal Necrolysis Erythema Multiforme 

Notes

Disclosure Statement

Zachary Cardone and Jason Bischoff have no disclosures.

Colin Kaide: Callibra, Inc.-Discharge 123 medical software company. Medical Advisory Board Portola Pharmaceuticals. I have no relationship with a commercial company that has a direct financial interest in subject matter or materials discussed in article or with a company making a competing product.

References

  1. 1.
    Assier H, Bastuji-Garin S, Revuz J, et al. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131:539–43.PubMedCrossRefGoogle Scholar
  2. 2.
    Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol. 1983;8:763.PubMedCrossRefGoogle Scholar
  4. 4.
    Wetter DA, Davis MD. Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007. J Am Acad Dermatol. 2010;62(1):45–53.PubMedCrossRefGoogle Scholar
  5. 5.
    Lerch M, Mainetti C, Beretta-Piccoli B, Harr T. Current perspectives on erythema multiforme. Clin Rev Allergy Immunol. 2018;54:177–84.PubMedCrossRefGoogle Scholar
  6. 6.
    Roujeau J-C. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol. 1997;24:726–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Fromowitz JS, Ramos-Caro FA, Flowers FP. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol. 2007;46(10):1092–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Roujeau JC, Hosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol. 1990;23:1039–58.PubMedCrossRefGoogle Scholar
  9. 9.
    Bircher A. Symptoms and danger signs in acute drug hypersensitivity. Toxicology. 2005;209:201–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Weston WL. Herpes-associated erythema multiforme. J Investig Dermatol. 2005;124:xv–xvi.PubMedCrossRefGoogle Scholar
  11. 11.
    Volcheck GW. Clinical evaluation and management of drug hypersensitivity. Immunol Allergy Clin N Am. 2004;24:357–71.CrossRefGoogle Scholar
  12. 12.
    Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137(6):1240.PubMedCrossRefGoogle Scholar
  13. 13.
    Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, Walker AM. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43.PubMedCrossRefGoogle Scholar
  14. 14.
    Parrillo SJ. Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Allergy Asthma Rep. 2007;7(4):243–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2010;85(2):131.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA. Arch Dermatol. 1993;129(4):466–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Wang X-q, et al. Risk of a lamotrigine-related skin rash: current meta-analysis and postmarketing cohort analysis. Seizure. 2015;25:52–61.PubMedCrossRefGoogle Scholar
  20. 20.
    Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40:985–91.PubMedCrossRefGoogle Scholar
  21. 21.
    Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13(1):49–54.PubMedCrossRefGoogle Scholar
  22. 22.
    Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev. 2006;5(2):160.PubMedCrossRefGoogle Scholar
  23. 23.
    Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC, EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25.PubMedCrossRefGoogle Scholar
  24. 24.
    Sommers KR, Kong KM, Bui DT, Fruehauf JP, Holcombe RF. Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. Anti-Cancer Drugs. 2003;14(8):659.PubMedCrossRefGoogle Scholar
  25. 25.
    Roujeau JC. Immune mechanisms in drug allergy. Allergol Int. 2006;55(1):27.PubMedCrossRefGoogle Scholar
  26. 26.
    Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272.PubMedCrossRefGoogle Scholar
  27. 27.
    Kohanim S, Palioura S, Saeed HN, et al. Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis – a comprehensive review and guide to therapy. II. Ophthalmic disease. Ocul Surf. 2016;14:168–88.PubMedCrossRefGoogle Scholar
  28. 28.
    Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case–control analysis. Clin Pharmacol Ther. 2010;88:60–8.PubMedCrossRefGoogle Scholar
  29. 29.
    de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, Van Nhieu JT, Duong TA, Chosidow O, Wolkenstein P, Brun-Buisson C, Maître B. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med. 2014;42(1):118.PubMedCrossRefGoogle Scholar
  30. 30.
    Sakai N, Yoshizawa Y, Amano A, Higashi N, Aoki M, Seo T, Suzuki K, Tanaka S, Tsukui T, Sakamoto C, Arai M, Yamamoto Y, Kawana S. Toxic epidermal necrolysis complicated by multiple intestinal ulcers. Int J Dermatol. 2008;47(2):180–2.PubMedCrossRefGoogle Scholar
  31. 31.
    Carter FM, Mitchell CK. Toxic epidermal necrolysis–an unusual cause of colonic perforation. Report of a case. Dis Colon Rectum. 1993;36(8):773–7.PubMedCrossRefGoogle Scholar
  32. 32.
    McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg. 1998;102:1018–22.PubMedCrossRefGoogle Scholar
  33. 33.
    Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23:87–96.PubMedCrossRefGoogle Scholar
  34. 34.
    Mahar PD, Wasiak J, Hii B, et al. A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centers. Burns. 2014;40:1245–54.PubMedCrossRefGoogle Scholar
  35. 35.
    Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010;31:100–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Cancio LC, et al. Protocolized resuscitation of burn patients. Crit Care Clin. 2016;32(4):599–610.PubMedCrossRefGoogle Scholar
  37. 37.
    Creamer D, Walsh S, Dziewulski P, Exton L, Lee H, Dart J, Setterfield J, Bunker C, Ardern-Jones M, Watson K, Wong G, Philippidou M, Vercueil A, Martin R, Williams G, Shah M, Brown D, Williams P, Mohd Mustapa M, Smith C. U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults. Br J Dermatol. 2016;174:1194–227.PubMedCrossRefGoogle Scholar
  38. 38.
    Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149–53.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Zachary E. Cardon
    • 1
  • Colin G. Kaide
    • 2
  • Jason J. Bischof
    • 1
    • 2
    Email author
  1. 1.The University of North Carolina School of Medicine, Department of Emergency MedicineColumbusUSA
  2. 2.Department of Emergency Medicine, Wexner Medical Center at The Ohio State UniversityColumbusUSA

Personalised recommendations